# OnCo record monika-hegi (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/monika-hegi/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "monika-hegi" ;
  schema:name "Monika E. Hegi"@en ;
  schema:description "Showed that MGMT promoter methylation predicts benefit from temozolomide, the biomarker every glioblastoma patient is now tested for."@en ;
  schema:url <https://onco.cc/people/monika-hegi/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Hegi%20ME%5BAuthor%5D%20MGMT> ;
  onco:tag "glioma", "biomarkers", "mgmt" ;
  schema:jobTitle "Professor and Head of the Laboratory of Brain Tumor Biology and Genetics, Lausanne University Hospital (CHUV)" ;
  schema:sameAs <https://orcid.org/0000-0003-0855-6495> ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/> ;
  onco:technologies <https://onco.cc/technologies/methylation-profiling/> ;
  onco:institutions <https://onco.cc/institutions/chuv-lausanne/> ;
  onco:trials <https://onco.cc/trials/eortc-26981/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-stupp-temozolomide-nejm-2005/> ;
  schema:affiliation <https://onco.cc/institutions/chuv-lausanne/> .